Single-cell RNA sequencing in prophylactic vaccine development | Andrés Noé et al. | ResearchPod

Transcript: Single-cell RNA sequencing in prophylactic vaccine development

[[RP_SECTION:single-cell-resolution-in-immunology|Single-cell resolution in immunology]]

Alex: [steady, analytical] Single-cell RNA sequencing lets us resolve the immune system into distinct cellular states, and it turns out vaccine efficacy often hinges on rare, protective subsets that bulk sequencing simply averages away.

Sam: [curious, leaning in] So we've been missing the signal of protection because it's buried in the noise of the majority population. Is that the core claim here?

Alex: [nodding] That's what Noé and colleagues lay out in their review on the future of systems immunology.

Sam: [thoughtful] How do you actually distinguish a protective cell from a bystander? Is it gene expression alone, or something more specific?

Alex: [deliberate, teaching mode] It's about linking phenotype to identity. By capturing the transcriptome alongside the antigen-receptor sequence, you can trace the ancestry and fate of individual cells — effectively turning the immune system into a lineage tree you can follow.

Sam: [processing] So it's not just a snapshot of what a cell is doing, but a record of its history. Does that explain why some volunteers in malaria challenge studies end up protected while others aren't, despite having similar antibody titers?

Alex: [confirming] It does. Bulk RNA-seq often shows no difference between those groups at all. But single-cell resolution turns up specific, rare memory precursor subsets that exist only in the protected individuals. [[RP_SECTION:technical-limitations-and-trade-offs|Technical limitations and trade-offs]]

Sam: [probing] That's a meaningful gap to close. But if you're hunting for rare subsets, don't you run into drop-out — transcripts getting missed simply because capture efficiency is low?

Alex: [measured, acknowledging the limitation] That's the primary constraint. If a rare cell type expresses a marker at low levels, drop-out can make it functionally invisible. High-depth sequencing helps you reach saturation, but that costs more and reduces the total number of cells you can profile — which is exactly the trade-off you're trying to avoid. [[RP_SECTION:dissociation-and-nuclear-sequencing|Dissociation and nuclear sequencing]]

Sam: [probing] And the physical process of pulling cells out of tissue — does dissociation itself distort the transcriptional state you're trying to measure?

Alex: [nodding] It's a real confound. Enzymatic or mechanical stress during dissociation can induce artificial gene expression — a stress signature that masks the true biological state of the cell. It's part of why some labs are shifting toward sequencing nuclei instead of whole cells.

Single-cell RNA sequencing in prophylactic vaccine development

Andrés Noé, Tamsin N Cargill, Carolyn M Nielsen, Andrew J C Russell, Eleanor Barnes

Jan 1, 2020·3:58·pmc·Original Paper

Single-cell RNA sequencingSystems immunologyProphylactic vaccine developmentSingle-cell RNA sequencing (scRNA-seq)Immunological memoryTranscriptome

Listen

4 min

Briefing

The Shift to Single-Cell Vaccinology

Traditional methods for evaluating vaccines, such as ELISA or flow cytometry, provide valuable but limited snapshots of the immune response. They often measure aggregate responses, which can mask the heterogeneity of individual immune cells. Single-cell RNA sequencing (scRNA-seq) addresses this by profiling the transcriptome of thousands of individual cells, offering an unprecedented view of how specific immune subsets—such as T cells, B cells, and innate immune cells—respond to vaccination. This approach is transforming systems immunology by allowing researchers to move beyond broad correlates of protection toward a mechanistic understanding of vaccine-induced immunity.

Applications in Vaccine Development

scRNA-seq is particularly powerful for comparing different vaccine platforms and regimens. By analyzing the transcriptional programs of antigen-specific cells, researchers can identify which adjuvants or delivery routes trigger the most effective innate activation or long-lived memory responses. Furthermore, the technology allows for the simultaneous reconstruction of B-cell and T-cell receptor sequences alongside transcriptomic data. This "clonal barcode" approach links a cell's ancestry and antigen specificity to its functional state, providing a roadmap for identifying the most immunogenic epitopes and understanding why certain individuals achieve better protection than others.

Overcoming Technical and Analytical Hurdles

While promising, the widespread adoption of scRNA-seq in clinical vaccinology is not without obstacles. The process requires careful sample preparation, as mechanical or enzymatic dissociation can inadvertently alter gene expression. Additionally, researchers must account for technical noise, such as "drop-out" events where transcripts are missed, and the fact that mRNA levels do not always correlate perfectly with protein abundance. To maximize the utility of these studies, the authors emphasize the importance of integrating scRNA-seq with other "omics" technologies—such as CITE-seq for surface proteins or spatial transcriptomics—to capture a more complete picture of the immune landscape.

Why It Matters

By providing a high-resolution view of the immune system, scRNA-seq allows for the identification of previously unappreciated biomarkers of vaccine success. This is especially critical for high-risk populations, such as the elderly or immunocompromised, where standard vaccine responses are often suboptimal. As the technology becomes more scalable and cost-effective, it will likely become a standard tool for streamlining the development of next-generation vaccines, from infectious disease prevention to personalized cancer immunotherapies.

Key Terms and Definitions

scRNA-seq — A suite of technologies used to profile the gene expression of individual cells, allowing for the identification of cellular heterogeneity within a tissue or immune sample.
Bulk RNA-seq — A traditional sequencing approach that pools thousands of cells together, providing an average gene expression profile that obscures differences between individual cell types.
Clonal Barcode — The unique sequence of a B-cell or T-cell receptor that acts as a genetic identifier, allowing researchers to track the ancestry and expansion of specific immune cell clones.
Pseudotime — A computational method used to order cells along a trajectory based on transcriptional changes, helping to infer the developmental path or differentiation state of immune cells over time.
Dual scRNA-seq — A specialized approach that simultaneously sequences the transcriptomes of both the host immune cells and an infecting pathogen, providing deep insights into host-pathogen interactions.

Abstract

Single-cell RNA sequencing allows highly detailed profiling of cellular immune responses from limited-volume samples, advancing prospects of a new era of systems immunology. The power of single-cell RNA sequencing offers various opportunities to decipher the immune response to infectious diseases and vaccines. Here, we describe the potential uses of single-cell RNA sequencing methods in prophylactic vaccine development, concentrating on infectious diseases including COVID-19. Using examples from several diseases, we review how single-cell RNA sequencing has been used to evaluate the immunological response to different vaccine platforms and regimens. By highlighting published and unpublished single-cell RNA sequencing studies relevant to vaccinology, we discuss some general considerations how the field could be enriched with the widespread adoption of this technology.

Single-cell RNA sequencing in prophylactic vaccine development: Research Paper Podcast